Clinical Trial Update: Study of a Neurocognition Enhancing Agent in Patients With Schizophrenia [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 study evaluating a neurocognition enhancing agent for schizophrenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Neurocognition Enhancing Agent

Snippet

Sponsor: National Research Foundation, Singapore | Conditions: Schizophrenia | Phase 2, Phase 3 | Status: COMPLETED